所有图片(1)
别名:
1-环丙基-6-氟-4-氧代-7(1-哌嗪基)-1,4-二氢喹啉-3-羧酸, 西普乐
经验公式（希尔记法）:
C17H18FN3O3
CAS号:
分子量:
331.34
Beilstein:
3568352
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
推荐产品
等级
pharmaceutical primary standard
API类
ciprofloxacin
制造商/商品名称
EDQM
技术
HPLC: suitable
gas chromatography (GC): suitable
应用
pharmaceutical (small molecule)
格式
neat
储存温度
2-8°C
SMILES字符串
OC(=O)C1=CN(C2CC2)c3cc(N4CCNCC4)c(F)cc3C1=O
InChI
1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)
InChI key
MYSWGUAQZAJSOK-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Ciprofloxacin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
WGK
WGK 2
Florentia Kaguelidou et al.
The Pediatric infectious disease journal, 30(2), e29-e37 (2010-11-05)
ciprofloxacin has no marketing authorization for use in neonates worldwide but it is prescribed for the treatment of neonatal life-threatening infections, mainly in developing countries and in Europe. Given the concerns about its toxicity in this population and the necessity
D Rodríguez-Pardo et al.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 20(11), O911-O919 (2014-04-29)
We aim to evaluate the epidemiology and outcome of gram-negative prosthetic joint infection (GN-PJI) treated with debridement, antibiotics and implant retention (DAIR), identify factors predictive of failure, and determine the impact of ciprofloxacin use on prognosis. We performed a retrospective
Mark D P Willcox
Clinical & experimental optometry, 94(2), 161-168 (2010-11-19)
Microbial keratitis is a rare disease but most commonly caused by bacterial infection. Two of the most common bacteria to cause microbial keratitis are Pseudomonas aeruginosa and Staphylococcus aureus. Antibiotic therapy to treat keratitis caused by these bacteria is either
Elisabet Marti et al.
Water research, 61, 67-76 (2014-06-02)
In this study we characterised the ciprofloxacin-resistant strains isolated in biofilm and sediments from a wastewater treatment plant (WWTP) discharge point and its receiving river. We also examined the prevalence of qnrA, qnrB, qnrS and aac(6')-Ib-cr genes in these isolates
David J Serisier et al.
Thorax, 68(9), 812-817 (2013-05-18)
The delivery of antipseudomonal antibiotics by inhalation to Pseudomonas aeruginosa-infected subjects with non-cystic fibrosis (CF) bronchiectasis is a logical extension of treatment strategies successfully developed in CF bronchiectasis. Dual release ciprofloxacin for inhalation (DRCFI) contains liposomal ciprofloxacin, formulated to optimise
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门